Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.

MLA

Ballard, Clive G., et al. “Long-Term Evaluation of Open-Label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis.” Parkinsonism & Related Disorders, vol. 77, Aug. 2020, pp. 100–06. EBSCOhost, https://doi.org/10.1016/j.parkreldis.2020.06.026.

APA

Ballard, C. G., Kreitzman, D. L., Isaacson, S., Liu, I.-Y., Norton, J. C., Demos, G., Fernandez, H. H., Ilic, T. V., Azulay, J.-P., Ferreira, J. J., Abler, V., Stankovic, S., & 015 Study Group. (2020). Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson’s disease psychosis. Parkinsonism & Related Disorders, 77, 100–106. https://doi.org/10.1016/j.parkreldis.2020.06.026

Chicago

Ballard, Clive G., David L. Kreitzman, Stuart Isaacson, I-Yuan Liu, James C. Norton, George Demos, Hubert H. Fernandez, et al. 2020. “Long-Term Evaluation of Open-Label Pimavanserin Safety and Tolerability in Parkinson’s Disease Psychosis.” Parkinsonism & Related Disorders 77 (August): 100–106. doi:10.1016/j.parkreldis.2020.06.026.